Advent Technologies (ADN) Tops Q2 EPS by 4c

Advent Technologies (NASDAQ: ADN) reported Q2 EPS of $, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.25 million.

“As a public company, we continue to see strong demand for our products from existing and new customers, especially following the acquisition of UltraCell LLC,” said Dr. Vasilis Gregoriou, Chairman and CEO of Advent Technologies. “The strong revenue growth in the quarter continues to demonstrate market interest in high-temperature proton exchange membrane (HT-PEM) based products. We are confident that many of our customers are on a fast growth trajectory and our HT-PEM based products are an enabling technology that will serve their needs.”

For earnings history and earnings-related data on Advent Technologies (ADN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c